X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the terms of the agreement, AUM and Asymchem agree to collaborate on the process development, and the clinical and commercial production, of AUM 601, which is a highly selective oral small-molecule inhibitor of the tropomyosin receptor kinase for treating rare cancers.
Lead Product(s): AUM601
Therapeutic Area: Oncology Product Name: AUM601
Highest Development Status: Phase IProduct Type: Small molecule
Recipient: AUM Biosciences
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration January 11, 2022
Details:
The partnership between Asymchem and LaNova will include small molecule drugs, monoclonal antibodies, double antibodies, ADC projects and potentially other R&D and production initiatives.
Lead Product(s): Antibody-drug Conjugates
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Large molecule
Partner/Sponsor/Collaborator: LaNova
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership September 16, 2021
Details:
Under the terms of the agreement, Asymchem will implement fermentation, verify protein expression and ultimately fine-tune the technology suitable for production of MS1819.
Lead Product(s): MS1819,Porcine enzyme replacement therapy
Therapeutic Area: Endocrinology Product Name: MS1819
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: AzurRx BioPharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership November 10, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
